Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Launches collaborative centre for translational research in head and neck cancer
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Subscribe To Our Newsletter & Stay Updated
